Literature DB >> 8912844

Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines.

X H Liu1, D P Rose.   

Abstract

Cyclooxygenase (COX), also referred to as prostaglandin endoperoxide synthase, is the rate-limiting enzyme for the metabolic conversion of arachidonic acid to prostaglandins (PGs) and related eicosanoids. Some human breast cancers synthesize large quantities of PGE2, but the regulatory mechanisms involved are unclear. We have examined the expression of the two isoforms of this enzyme, COX-1 and COX-2, their regulation by tetradecanoyl phorbol acetate (TPA), and the associated PGE2 production in two human breast cancer cell lines with different biological phenotypes. Estrogen-dependent MCF-7 cells exhibited a relatively high expression of COX-1; COX-2 was barely detectable but was transiently induced by treatment with TPA (10 nM). In contrast, the estrogen-independent, highly invasive, metastatic MDA-MB-231 cell line showed a low expression of COX-1 but a high constitutive level of COX-2. This high COX-2 expression applied to both the protein and mRNA and increased further over a relatively long period of time in the presence of TPA. The extent of PGE2 production by the two cell lines correlated well with the level of COX-2 protein, suggesting that this isoform is required for both their constitutive and mitogen-induced PGE2 synthesis. Moreover, overexpression and persistent expression of COX-2 may be influenced by breast tumor hormone status and seem to be a feature of the aggressive, metastatic phenotype.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8912844

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors.

Authors:  T Koshiba; R Hosotani; Y Miyamoto; M Wada; J U Lee; K Fujimoto; S Tsuji; S Nakajima; R Doi; M Imamura
Journal:  Int J Pancreatol       Date:  1999-10

Review 2.  Cyclooxygenase-2 and thromboxane synthase in non-endocrine and endocrine tumors: a review.

Authors:  Onder Onguru; Mary B Casey; Sabine Kajita; Nobuki Nakamura; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

3.  The value of COX-2 expression in the prognostic parameters of invasive ductal carcinoma of the breast.

Authors:  Nagehan Ozdemir Barısık; Sevinc Hallac Keser; Aylin Ege Gul; Sibel Sensu; Nilufer Onak Kandemir; Hasan Fehmi Kucuk; Mahmut Gumus; Nimet Karadayı
Journal:  Med Oncol       Date:  2010-03-31       Impact factor: 3.064

4.  Epstein-Barr virus protein can upregulate cyclo-oxygenase-2 expression through association with the suppressor of metastasis Nm23-H1.

Authors:  Rajeev Kaul; Subhash C Verma; Masanao Murakami; Ke Lan; Tathagata Choudhuri; Erle S Robertson
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  Cyclo-oxygenase 2 and breast cancer prevention. Non-steroidal anti-inflammatory agents are worth testing in breast cancer.

Authors:  H Vainio; G Morgan
Journal:  BMJ       Date:  1998-09-26

6.  Five COX-2 gene polymorphisms and risk of breast cancer: an updated meta-analysis based on 19 case-control studies.

Authors:  Qing Li; Liu Liu; Yanling Liu; Huirong Zhou; Zhi Yang; Keng Yuan; Weiping Min
Journal:  Med Oncol       Date:  2014-11-30       Impact factor: 3.064

7.  Genistein at maximal physiologic serum levels induces G0/G1 arrest in MCF-7 and HB4a cells, but not apoptosis.

Authors:  Marcela S Tsuboy; Juliana C Marcarini; Alecsandra O de Souza; Natália A de Paula; Daniel J Dorta; Mário S Mantovani; Lucia R Ribeiro
Journal:  J Med Food       Date:  2013-12-10       Impact factor: 2.786

8.  A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.

Authors:  Elaine T Lam; Cindy L O'Bryant; Michele Basche; Daniel L Gustafson; Natalie Serkova; Anna Baron; Scott N Holden; Janet Dancey; S Gail Eckhardt; Lia Gore
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

9.  CK1epsilon is required for breast cancers dependent on beta-catenin activity.

Authors:  So Young Kim; Ian F Dunn; Ron Firestein; Piyush Gupta; Leslie Wardwell; Kara Repich; Anna C Schinzel; Ben Wittner; Serena J Silver; David E Root; Jesse S Boehm; Sridhar Ramaswamy; Eric S Lander; William C Hahn
Journal:  PLoS One       Date:  2010-02-01       Impact factor: 3.240

10.  Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells.

Authors:  C Martínez-Campa; A González; M D Mediavilla; C Alonso-González; V Alvarez-García; E J Sánchez-Barceló; S Cos
Journal:  Br J Cancer       Date:  2009-09-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.